TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2201256
Drug: 4-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-hour infusion of amphotericin B (group B)
Study: 6109538
Drug: Betaxolol 10
Normalized name: betaxolol 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 10 mg daily for 7 days
Study: 6109538
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg daily for 7 days
Study: 6109538
Drug: Betaxolol increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol increasing doses up to 60 mg/day for 15 days
Study: 31574792
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy (GCBT) for 8 consecutive weeks, 2.5-hour sessions each week
Study: 19181592
Drug: Rocuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.06 mg/kg as a priming dose
Study: 19181592
Drug: Cisatracurium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.01 mg/kg as a priming dose
Study: 14725687
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg/orally, twice daily)
Study: 14725687
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg/orally, twice daily)
Study: 14725687
Drug: Combined metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metformin (850 mg/orally, twice daily) + flutamide (250 mg/orally, twice daily)
Study: 10506726
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment group
Study: 31990246
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin C, thiamine and hydrocortisone
Study: 31990246
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (control group)
Study: 28193240
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg/day) for 4 weeks instead of ethambutol
Study: 28193240
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg/day) for 2 weeks instead of ethambutol
Study: 28193240
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol)
Study: 28193240
Drug: Treatment success
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment success rate
Study: 17202116
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone replacement
Study: 16086931
Drug: Cholesterol-lowering medications
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering medications
Study: 11981766
Drug: Transarterial Lipiodol
Normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial Lipiodol chemoembolization (variable dose of cisplatin in Lipiodol and gelatin-sponge particles, median 4.5 courses per patient)
Study: 9818107
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine (8 mg)
Study: 9818107
Drug: 1% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% hyperbaric bupivacaine (8 mg)
Study: 7543348
Drug: Tenidap 120
Normalized name: tenidap
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap 120 mg/day (once daily)
Study: 7543348
Drug: Diclofenac 150
Normalized name: diclofenac sodium 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 150 mg/day (50 mg t.i.d)
Study: 30926298
Drug: Cervarix® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix® vaccine
Study: 30926298
Drug: Gardasil® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil® vaccine
Study: 30926298
Drug: Non-vaccine types
Normalized name: Adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vaccine types
Study: 25302637
Drug: Pea hull
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea hull fibre (7 g)
Study: 25302637
Drug: Pea protein
Normalized name: Pea Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea protein (10 g)
Study: 25302637
Drug: Pea protein
Normalized name: Pea Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea protein (10 g) plus hull fibre (7 g)
Study: 25302637
Drug: Yellow peas
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow peas (406 g)
Study: 19780738
Drug: Doxycycline capsules
Normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline capsules 100 mg twice daily plus triple sulfa vaginal cream once daily for ten days
Study: 19780738
Drug: Doxycycline capsules
Normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline capsules 100 mg twice daily and triple sulfa vaginal cream once daily plus vitamin C tablets 250 mg once daily for ten days
Study: 17206698
Drug: Group-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based intervention program consisting of nine weekly sessions, alternating lectures and group therapy sessions.
Study: 15315180
Drug: Propofol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (6 mg/kg/h)
Study: 8285592
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy in asymptomatic patients (Mayo asymptomatic trial, Carotid Artery Stenosis with Asymptomatic Narrowing: Operation Versus Aspirin trial, VA Asymptomatic Trial)
Study: 29473908
Drug: l-carnitine-l-tartrate 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine-l-tartrate 1500 mg per day
Study: 27328737
Drug: Dexamethasone 0.15
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.15 mg·kg(‐1) IV plus sham acupuncture
Study: 27328737
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at P6 bilaterally and CV13 plus 2 ml of normal saline IV
Study: 14513588
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of immunoglobulin yolk antibodies (IgY) spray (n = 9)
Study: 14513588
Drug: 0.15% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% chlorhexidine (CH) spray (positive control group, n = 9)
Study: 14513588
Drug: Placebo phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo phosphate buffered saline (PBS) spray (negative control group, n = 6)
Study: 10526263
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with cisplatin (200 mg) and epirubicin (120 mg) via the external carotid artery
Study: 10526263
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (46 grays)
Study: 8722937
Drug: Oral teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral teicoplanin
Study: 8722937
Drug: Oral fusidic
Normalized name: fusidate
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fusidic acid
Study: 29873727
Drug: Zilpaterol hydrochloride
Normalized name: zilpaterol hydrochloride
DrugBank: Zilpaterol (DB11479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilpaterol hydrochloride (ZH) supplementation (90 mg.d‐1 per steer for 20 d)
Study: 21918977
Drug: Preoperative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative serum CA-125 levels above 30 U/ml
Study: 20113825
Drug: Trastuzumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (1 year of treatment, given as neoadjuvant and adjuvant treatment)
Study: 15471363
Drug: Ibudilast (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (60 mg/day p.o. for four weeks)
Study: 11531934
Drug: 1alpha‐hydroxyvitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1alpha‐hydroxyvitamin D3 + sequential combined HRT + calcium supplement
Study: 11531934
Drug: sequential combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential combined HRT + calcium supplement
Study: 3071594
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care (standardized intensive drug treatment)
Study: 24886626
Drug: Extra-virgin olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-virgin olive oil consumption increase by 10 g/d
Study: 18408580
Drug: Neoral C2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral C2 monitoring with high range (1600-1800 ng/mL)
Study: 18408580
Drug: Neoral C2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral C2 monitoring with intermediate range (1400-1600 ng/mL)
Study: 18408580
Drug: Neoral C2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral C2 monitoring with low range (1200-1400 ng/mL)
Study: 15816467
Drug: Cimetidine (CIM)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (CIM) administered perioperatively, initiated 7 days before operation and continued until 10 days after surgery.
Study: 14695785
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cimetidine treatment).
Study: 14695785
Drug: Cimetidine (CIM)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (CIM) treatment.
Study: 12459936
Drug: Clodronate 400-800
Normalized name: clodronic acid 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 400-800 mg
Study: 10379611
Drug: Dorzolamide eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide eye drops applied three times daily for 3 days
Study: 10379611
Drug: Placebo preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparation applied according to the same protocol
Study: 8540451
Drug: Beta-blocker group
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker group (n = 58)
Study: 1907662
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (76 patients)
Study: 6138120
Drug: Trimeprazine (sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimeprazine (sedative H1 antihistamine)
Study: 6138120
Drug: Nitrazepam (sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam (sedative benzodiazepine)
Study: 6138120
Drug: Astemizole (non-sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (non-sedative H1 antihistamine)
Study: 6138120
Drug: Terfenadine (non-sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (non-sedative H1 antihistamine)
Study: 25637614
Drug: Directed Osteopathic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed Osteopathic Manipulative Treatment (D-OMT)
Study: 25637614
Drug: Nondirected Osteopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondirected Osteopathic Manipulative Treatment (ND-OMT)
Study: 15849222
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (with or without trastuzumab)
Study: 12040975
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate for 2 months
Study: 3080622
Drug: Unbalanced amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbalanced amino acid solutions (essential amino acids, branched‐chain amino acids)
Study: 3080622
Drug: Balanced and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced and complete amino acid solution
Study: 22048172
Drug: HPV-6/11/16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-6/11/16/18 vaccine
Study: 28987287
Drug: Potentially effective
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially effective low-risk treatments for weight-loss devices
Study: 28987287
Drug: Potentially less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially less effective and riskier treatments for weight-loss devices
Study: 26781700
Drug: Ready-to-eat food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-eat food product (Vita-Weat biscuit) as part of a diet prescription for weight loss
Study: 24552306
Drug: Antituberculosis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculosis therapy
Study: 9855212
Drug: Distension combined
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distension combined with steroid
Study: 9855212
Drug: Steroid alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid alone
Study: 2651106
Drug: Sodium acetate
Normalized name: Sodium Acetate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium acetate infusion at 2.5 mmoles/min for 60 min
Study: 29090685
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg, 3 monthly infusions)
Study: 28463714
Drug: Antipsychotic medication-alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication-alone
Study: 26323969
Drug: Gamma Delta
Normalized name: Allogeneic enriched variable delta 1 gamma delta T-cells
DrugBank: GDX012 (DB18448)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma Delta Tocotrienol (GDT) - 2 capsules of 300 mg (450 mg γ‐T3 and 150 mg δ‐T3)
Study: 26323969
Drug: Tocotrienol-Rich Fraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol-Rich Fraction (TRF) - 4 capsules of 200 mg (451.2 mg γ‐T3 & 102.72 mg δ‐T3)
Study: 24548399
Drug: recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: recombinant tissue plasminogen activator (rt‐PA) and parental anticoagulant
Study: 18303156
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1 mg, 0.04 ml)
Study: 18303156
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) plus intravitreal triamcinolone (4 mg)
Study: 10352330
Drug: Control (historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (historical controls without G‐CSF)
Study: 28969711
Drug: n‐3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 LCPUFA supplements
Study: 24519631
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine with 15 μg·mL(‐1) hydromorphone (LA group)
Study: 15284305
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no digoxin therapy)
Study: 8427134
Drug: Sequential pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential pulse shocks
Study: 3676051
Drug: Conventional inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional inhalation induction technique with isoflurane in nitrous oxide and oxygen
Study: 28669167
Drug: Leukocytosis (WBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytosis (WBC > 9 x 10^9/L)
Study: 28669167
Drug: Normal WBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal WBC (WBC ≤ 9 x 10^9/L)
Study: 28669167
Drug: Anemia (Hgb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia (Hgb < 110 g/L)
Study: 28669167
Drug: Normal Hgb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Hgb (Hgb ≥ 110 g/L)
Study: 28669167
Drug: Thrombocytosis (Plt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombocytosis (Plt > 350 x 10^9/L)
Study: 20169458
Drug: Experimental solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental solution (SnCl(2) with 1,900 ppm Sn(2+) and 1,000 ppm F(-), pH 4.5)
Study: 19930833
Drug: Embolization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embolization of the draining veins with absolute ethanol followed by bleomycin A5 hydrochloride intra-tumoural injection
Study: 19930833
Drug: Intra-tumoural injection
Normalized name: TUMOUR DETECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-tumoural injection only
Study: 16767966
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamethasone intravenously before induction of anesthesia
Study: 16767966
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% normal saline 2 ml)
Study: 9052476
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (orchidectomy or luteinizing hormone-releasing hormone analogue)
Study: 8336880
Drug: Extra-amniotic saline
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic saline infusion plus intracervical Foley catheter balloon
Study: 8336880
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal gel (2.85 mg)
Study: 3096164
Drug: Alfentanil bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil bolus injection (n = 15) over 3 s
Study: 3096164
Drug: Alfentanil slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil slow injection (n = 15) over 30 s
Study: 3096164
Drug: Succinylcholine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (25 mg i.v.)
Study: 31276809
Drug: High-dose Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Fentanyl Sublingual Spray (FSS) (35%-45% of total daily opioid dose)
Study: 31276809
Drug: Low-dose Fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Fentanyl Sublingual Spray (FSS) (15%-25% of total daily opioid dose)
Study: 31276809
Drug: High-dose Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Fentanyl Sublingual Spray (FSS)
Study: 21813882
Drug: Autologous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fat transplantation (Group A; 12-165 mL per session)
Study: 21813882
Drug: Adipose-derived stem
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose-derived stem cell-enriched lipografts (Group B; 8-155 mL per session)
Study: 16735482
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein preload (50 g, 1.1 MJ, 450 ml)
Study: 16735482
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein preload (50 g, 1.1 MJ, 450 ml)
Study: 16735482
Drug: Gluten protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten protein preload (50 g, 1.1 MJ, 450 ml)
Study: 16735482
Drug: Glucose treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose treatment
Study: 15331551
Drug: Intravenous exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous exenatide (0.066 pmol.kg(‐1).min(‐1))
Study: 9156366
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA) at 200 mumol
Study: 9156366
Drug: Intraarterial L‐NMMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial L‐NMMA (8 mumol/min for 5 min)
Study: 8333471
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot (3.75 mg injected monthly)
Study: 8333471
Drug: Danazol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (800 mg administered orally daily)
Study: 29965967
Drug: MJ8VAX (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MJ8VAX (50 μg of peptide conjugate J8-DT)
Study: 19160429
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/d for 6 months
Study: 12105320
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/d for 30 days)
Study: 6457060
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d disodium dichloromethylene diphosphonate (Cl2MDP)
Study: 6457060
Drug: 1,600 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,600 mg/d disodium dichloromethylene diphosphonate (Cl2MDP)
Study: 31610101
Drug: BHV-0223 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHV-0223 (40 mg)
Study: 31610101
Drug: BHV-0223 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHV-0223 (40 mg) under fed conditions
Study: 31610101
Drug: Oral riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral riluzole tablets (50 mg)
Study: 24291054
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg P. emblica extract
Study: 24291054
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg ecosprin
Study: 24291054
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg P. emblica + 75 mg clopidogrel
Study: 24291054
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg P. emblica + 75 mg ecosprin
Study: 24291054
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg P. emblica extract (twice daily)
Study: 24291054
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel (once daily)
Study: 24291054
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg ecosprin (once daily)
Study: 19755613
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg daily for 4 weeks
Study: 11600564
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment in subjects with null mutations
Study: 11600564
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment in subjects with defective mutations
Study: 9637897
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg/kg/day)
Study: 9637897
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (lower dosage)